Moving a biologic from development into commercial manufacturing involves significant challenges due to differences in equipment, materials, and operating conditions. For pharmaceutical sponsors, successful technology transfer means maintaining product quality and avoiding costly delays. As biologics become more complex, early identification of potential problems is critical to ensure smooth production transitions.
Standardized procedures and enhanced collaboration among technical teams are essential for managing risks during the transfer process. WuXi Biologics emphasizes the importance of early risk assessment and the application of process knowledge to improve commercial readiness. By employing a multidimensional risk-assessment approach, sponsors can expose hidden gaps that may affect product quality and timelines. This proactive strategy can lead to faster and more reliable technology transfers, ultimately benefiting manufacturers and suppliers by ensuring consistent production and supply chain resilience.
Source: contractpharma.com · Image: Naitō Museum of Pharmaceutical Science and Industry 20210529 06 by 先従隗始, CC0, via Wikimedia Commons
Start your 7-day trial and see what the database can do →
